期刊
CLINICAL ONCOLOGY
卷 22, 期 6, 页码 448-455出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.clon.2010.04.008
关键词
Refractory thyroid cancer; targeted therapy
类别
资金
- Amgen
- Astra-Zeneca
- Bayer
- BMS-Exelixis
- Esai
- Genzyme
- Ipsen Pharma
The recent availability of molecular targeted therapies leads to reconsideration of the treatment strategy in patients with distant metastases from differentiated thyroid carcinoma who are resistant to radioiodine therapy, and in patients with metastatic medullary thyroid carcinoma. In patients with progressive disease, treatment with kinase inhibitors should be offered, preferably in the context of a prospective trial. (C) 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据